A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus

ABSTRACTAnnually, ∼0.6% of newborns in the United States and European Union are congenitally infected with human cytomegalovirus (CMV); ∼20% of these infected newborns are symptomatic at birth or have developmental sequelae. The lack of an effective therapy for maternal infection hinders routine ser